Navigation Links
CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
Date:11/12/2009

IRVINE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, and CareFusion (NYSE: CFN), a leading global medical device company, today announced a multi-year technology licensing agreement establishing the breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology to be used in CareFusion infusion and respiratory products under development*.

Incorporating Masimo Rainbow SET Pulse CO-Oximetry technology will enable CareFusion's future infusion and respiratory products (under development*) to noninvasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise. The ability to automatically assess total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI® for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate directly from CareFusion's ventilators and infusion pumps may facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions.

Currently, CareFusion uses Masimo technology in the Alaris® SpO2 module to help safeguard PCA delivery through the Alaris® System. The Alaris® PCA module together with the Alaris® SpO2 module--featuring Masimo SET® pulse oximetry technology for accurate and trustworthy measure-through motion and low-perfusion SpO2, pulse rate, and perfusion index measurements--provides an additional safety net for risk
'/>"/>

SOURCE Masimo
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
2. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
3. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
4. CareFusion Moves First Quarter Earnings Announcement to November 5
5. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
11. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Henry ... world,s largest provider of health care products and ... practitioners, announced today that Stanley M. Bergman, Henry Schein,s Chairman ... participate in a healthcare services panel at the ... Mr. Bergman will be Dr. Stohler, Dean of ...
(Date:9/15/2014)... PARIS and NEW YORK ... company Pharnext SAS and the Hereditary Neuropathy Foundation (HNF) ... increase the awareness around Charcot-Marie-Tooth (CMT) disease and support ... community. Pharnext will provide financial support ... design and development of a specific section in the ...
(Date:9/15/2014)... WALTHAM, Mass. , Sept. 15, 2014  Alere Inc. ... a global leader in infectious disease, toxicology, cardiology and ... of former executives, led by former CEO Ron ... and Exchange Commission and subsequently sent a letter to ... requesting one month of due diligence in an effort ...
Breaking Medicine Technology:Henry Schein To Present At The Leerink Partners Services Roundtable 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Alere Responds To Letter From Former Executives 2
... NEWTON, Mass., Nov. 3, 2010 Karyopharm Therapeutics Inc., a leader ... $20M Series A financing. The nuclear transport machinery plays an integral ... spectrum of human and animal disease. Karyopharm is focused on the ... i nhibitors of n uclear ...
... that a new market research report is available in its ... http://www.reportlinker.com/p0324749/Quality-for-Biologics.html Quality for Biologics – ... change control, product variation, characterisation, and regulatory concerns ... than sales of small molecule drugs, which grew by not ...
Cached Medicine Technology:Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 2Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 3Reportlinker Adds Quality for Biologics 2Reportlinker Adds Quality for Biologics 3Reportlinker Adds Quality for Biologics 4Reportlinker Adds Quality for Biologics 5Reportlinker Adds Quality for Biologics 6
(Date:9/16/2014)... Terminsurancevirginia.com has released a new blog post ... insurance for obese clients. , Obese clients can ... It is unlikely for applicants to be denied coverage ... insurance costs. , Having life insurance is important ... insurance is available as temporary or permanent coverage and ...
(Date:9/16/2014)... Insuranceservicecompany.com has released a new blog ... investment tool. , Whole life insurance can provide financial ... used as an investment tool. Clients can save money for ... , A whole life insurance plan features a savings ... order for this policy to be profitable, clients should purchase ...
(Date:9/16/2014)... adage that warns against passing judgment based on ... species, apparently don,t share such human wisdom when ... University Polytechnic School of Engineering found that female ... fin color: yellow. The preference for yellow was ... , The reason may lie in the engineering-based, ...
(Date:9/16/2014)... According to a report by iData Research ( ... market research, the market for enteral feeding devices is ... U.S . and Europe combined. The market ... tubes, DPEJ tubes, PEG/J tubes. The enteral feeding replacement ... non-balloon tubes, nasogastric and nasojejunal tubes, enteral feeding pumps ...
(Date:9/16/2014)... 2014 Care Logistics® announced the ... of the Hospital Operating System™ that allows hospitals ... with staff capacity. For the first time, bed ... nursing and other staff capacity. , “The Demand ... anticipated admissions, discharges and transfers, real staff capacity ...
Breaking Medicine News(10 mins):Health News:Obese Clients Can Find Affordable No Exam Term Life Insurance at Terminsurancevirginia.com! 2Health News:Whole Life Insurance Can Be A Good Investment Tool for Retirement! 2Health News:Judging a fish by its color: for female bluefin killifish, love is a yellow mate 2Health News:Judging a fish by its color: for female bluefin killifish, love is a yellow mate 3Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 2Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 3Health News:Care Logistics Launches Demand Logistics as Part of the Hospital Operating System 2
... ) launches the GlaceComplete product suite which seamlessly integrates EMR ... billing process. The product has been designed to reduce the ... for the average office based medical practice. , ... ...
... piezoelectric transducers in industrial applications, and to facilitate transducer evaluation in ... ... 26, 2009 -- Piezoelectric elements have a myriad of uses. They ... in a structure. They can be used to acoustically cancel noise, ...
... that is responsible for maintaining the health of the light-sensing ... retina for the first time. , The ability to see ... of many diseases of the eye long before a patient ... Investigative Ophthalmology and Visual Science ., "Our goal is to ...
... Feb. 25 PharmaNet Development Group, Inc. (the "Company") ... clinical development services, today reported preliminary net income for ... million, or $0.08 per diluted share, compared to net ... per diluted share, in the fourth quarter 2007. All ...
... for February 26, 2009 at 10:00 a.m. EST , EAST ... SVNT ) today reported financial results for the three months and ... 2008, the Company had a net loss of $24.2 million, or ... the year ended December 31, 2008, the Company had a net ...
... with record bookings and continued positive cash flow ... AMCS ), a leader in radiology ... reported unaudited financial results for the fourth quarter ... http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ) Q4 Financial Highlights Revenue ...
Cached Medicine News:Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 3Health News:Amped Up Piezos Are On The Move - Driving Piezos with an Affordable High Voltage Piezo Amplifier QPA200 2Health News:Amped Up Piezos Are On The Move - Driving Piezos with an Affordable High Voltage Piezo Amplifier QPA200 3Health News:'Dark cells' of living retina imaged for the first time 2Health News:'Dark cells' of living retina imaged for the first time 3Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 2Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 3Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 4Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 5Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 6Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 7Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 8Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 9Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 10Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 11Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 12Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 13Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 14Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 15Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 16Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 17Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 2Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 3Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 4Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 5Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 6Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 7Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 8Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 9Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 3Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 4Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 5Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 6
... This new kit uses proteins produced with ... Latin America, and which are capable of detecting ... this area. They are proteins with amino acid ... antigen) antigen. During the acute phase of the ...
The Cellabs T. cruzi IgG CELISA is a direct ELISA kit designed to detect antibodies produced during T. cruzi infections (Chagas disease)....
... The Cypress quick test is a ... of antibodies to Trypanosoma cruzi. It ... or plasma. The method employs a unique ... which is conjugated on dye particles, and ...
... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
Medicine Products: